Global Avian Influenza Vaccines Market, By Vaccine Type (Inactivated Vaccines, Live Recombinant Vaccines, Combination Vaccines), Application (Chicken, Duck and Goose, Others), Strain (H5 Strain, H7 Strain, H9 Strain) – Industry Trends and Forecast to 2029
Market Analysis and Size
Avian influenza, commonly known as bird flu, is a viral virus that transmits from birds to other animals including people. The virus was discovered for the first time in China. In the following year, during an outbreak in Hong Kong, the Asian H5N1 strain was discovered, and it has since spread throughout Europe, Asia, North and South America, Africa, and the Middle East. Based on its molecular structure, avian influenza can be classified as highly pathogenic or low pathogenic. The virus is classified as H5N1, H7N3, H7N7, H7N9, and H9N2 depending on the strains. Furthermore, the virus of type A of subtype H5N1 is currently being studied as the most virulent avian influenza virus.
Data Bridge Market Research analyses that the avian influenza vaccines market was valued at USD 124.53 million in 2021 and is expected to reach USD 196.25 million by 2029, registering a CAGR of 5.85% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Vaccine Type (Inactivated Vaccines, Live Recombinant Vaccines, Combination Vaccines), Application (Chicken, Duck and Goose, Others), Strain (H5 Strain, H7 Strain, H9 Strain)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Mallinckrodt (US), Elanco (US), Boehringer Ingelheim International GmbH. (Germany), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Virbac (France), Vetoquinol (France), Zoetis (US), Ceva (France), Bimeda, Inc. (US), Phibro Animal Health Corporation (US), HIPRA (Spain), Medion (Germany), YEBIO BIOENGINEERING CO., LTD OF QINGDAO (China)
|
|
Market Opportunities
|
|
Market Definition
Avian influenza is an infectious disease caused by the type-A virus found in birds. Aquatic birds are the virus's most common carrier. The avian influenza type A virus is characterized as either neuraminidase (NA) or hemagglutinin (HA) based on protein remains on its surface (HA). It is classified as either highly pathogenic or low pathogenic based on molecular features. If the virus gets into the eyes, nose, or mouth, it can cause serious illness. For infection prevention and treatment, the antiviral drugs oseltamivir and zanamivir are included in the Avian Influenza Vaccines. Ducks, chickens, geese, and other birds are all known to consume it.
Avian Influenza Vaccines Market Dynamics
Drivers
- Surging frequency of illness in developing countries
The rise in frequency of illness in developing countries will act as a major driver that will result in the expansion of the growth rate of the market. Infections are becoming more common in developing countries, which could lead to an increase in poultry mortality. At the same time, the increased demand for chicken for human consumption demands additional research to develop effective disease-prevention vaccines. Using gene editing methods, chickens can be rendered resistant to avian flu. In addition, particular legislation allow for the eradication of hen bird flu.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of avian influenza vaccines market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness about avian influenza and rising healthcare expenditure will expand the avian influenza vaccines market. Additionally, increasing demand for poultry for consumption and rise in the number of outbreaks will result in the expansion of avian influenza vaccines market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the avian influenza vaccines market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
- Rise in the number of strategic collaborations
The increasing number of strategic collaborations will boost new as well as profitable market opportunities in the coming years. Strategic cooperation between commercial and government entities to develop healthcare solutions, as well as combined efforts in the digitalization of medical aid facilities, could help the industry flourish.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the avian influenza vaccines market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost associated with the drug distribution and development will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the avian influenza vaccines market. Additionally, unavailability of effective vaccine and the dearth of awareness among the people maintaining poultry will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This avian influenza vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the avian influenza vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Avian influenza vaccines market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Avian Influenza Vaccines Market
The COVID-19 outbreak was wreaking havoc on businesses and has already resulted in an unprecedented economic collapse. The impact of COVID-19 on healthcare systems around the world was putting a pressure on them. There is no proof that animals can transmit COVID-19 to humans. The belief that animals can carry the virus to people has resulted in an increase in the number of pets abandoned. COVID-19 has also affected the supply chain, resulting in a global shortage of animal health items such nutritional feed and immunizations. Many manufacturers in the animal health business have been left with a considerably diminished workforce, which had a huge influence on the industry. However, healthcare facilities are stocking up owing to the strong demand for animal health goods. Due to procurement inefficiencies and squandered speeding, this is projected to put additional financial strain on the market. Many hospitals and veterinary clinics are storing up on supplies due to the pandemic crisis.
Global Avian Influenza Vaccines Market Scope
The avian influenza vaccines market is segmented on the basis of vaccine type, application, and strain. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Vaccine Type
- Inactivated Vaccines
- Live Recombinant Vaccines
- Combination Vaccines
Application
- Chicken
- Duck and Goose
- Others
Strain
- H5 Strain
- H7 Strain
- H9 Strain
Avian Influenza Vaccines Market Regional Analysis/Insights
The avian influenza vaccines market is analysed and market size insights and trends are provided by country, vaccine type, application, and strain as referenced above.
The countries covered in the avian influenza vaccines market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the avian influenza vaccines market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising awareness among the people will further propel the market’s growth rate in this region. Along with this, growing number of research and development activities and rising healthcare expenditure will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to surging occurrences of infection in this region. Also, development of healthcare infrastructure and increasing dependence on poultry for protein will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Avian Influenza Vaccines Market Share Analysis
The avian influenza vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to avian influenza vaccines market.
Some of the major players operating in the avian influenza vaccines market are:
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mallinckrodt (US)
- Elanco (US)
- Boehringer Ingelheim International GmbH. (Germany)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Virbac (France)
- Vetoquinol (France)
- Zoetis (US)
- Ceva (France)
- Bimeda, Inc. (US)
- Phibro Animal Health Corporation (US)
- HIPRA (Spain)
- Medion (Germany)
- YEBIO BIOENGINEERING CO., LTD OF QINGDAO (China)
SKU-